Recently, anti-PD-1/PD-L1 therapy (atezolizumab, pembrolizumab, nivolumab) which could disrupt PD-1/PD-L1-mediated signaling and restore antitumor immunity had been reported to be a good treatment option for advanced NSCLC [5–18]. Here, CD274 is linked to non-small cell lung carcinoma.